Immuron q3 fy23 business update presentation

Melbourne, australia, april 19, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the q3 fy23 investor presentation for the business update webinar to be held today at 11:00 am (aest).
IMRN Ratings Summary
IMRN Quant Ranking